Nevro Corp., a global medical device company that delivers comprehensive, life-changing solutions for the treatment of chronic pain, announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1 SI Joint Fusion System (Nevro1). 

Nervo1 is a posterior integrated transfixation cage system that offers enhanced stability, minimized bone removal, and increased fusion potential compared to a posterolateral cylindrical threaded single-implant system. 

The study concurrently assessed and compared the fixation efficacy, invasiveness and fusion potential of a posterior integrated transfixation cage system (Nevro1) to the posterolateral threaded implant and lateral triangular rod systems.

Nevro1’s performance also showed that it is equivalent in osteopenic bone when compared to a lateral triangular rod system in healthy bone.

“The SI joint is a recognized contributor to low back pain, significantly affecting daily life for those impacted,” said Douglas Beall, MD, FIPP, FSIR, Chief of Services, Comprehensive Specialty Care, Clinical Radiology of Oklahoma. “This study demonstrates the advantages of the posterior integrated cage system that spans the SI joint to stabilize it and to address pain associated with SI joint dysfunction. The Nevro1 device represents a significant advancement in SI joint fusion, offering greater fixation with increased fusion potential, and minimal bone removal compared to other options I have for my patients.”

In the study, Nevro1 and the lateral triangular rods produced equivalent motion reduction in all motion planes. Posterolateral cylindrical threaded implant produced less motion reduction than Nevro1 and lateral implants in flexion-extension. The study also showed that using Nevro1 for the treatment of SI joint-related pain allows for the most surface area for fusion, which provides a significantly better opportunity for robust SI joint arthrodesis.

“These findings illustrate the potential benefits of the Nevro1 sacroiliac joint transfixing device, especially in terms of the post-surgical experience for the patient and opportunity for long-term fusion and improved patient outcomes,” said David Caraway MD, PhD, Nevro’s chief medical officer. “This latest study further establishes this technology as a promising treatment for patients suffering from SI joint pain.”